February 28, 2020. Efforts to improve inclusion of racial and ethnic minority populations in clinical trials need to include incentives that are more effective than merely asking companies to do so. Greater diversity would, in turn, improve the generalizability of clinical trial results and provide patients and health care professionals with the information necessary to make an informed decision about which products to use for which patients.
Read More »Tag: FDA
NCHR’s Testimony to FDA on TOOKAD to Treat Low-Risk Prostate Cancer
February 26, 2020. The long-term complications of TOOKAD to treat low-risk prostate cancer are unclear. We believe that better research needs to be completed before approval, especially because the sponsor did not comply with FDA’s recommendations for the study.
Read More »Top UA Health Executive has a Six-Figure Side Job as Corporate Consultant
Arizona Daily Star, February 18, 2020. This university dean is making more than $1 million each year, and 6 figures is from device companies. He says he made an honest mistake when he claimed the drug eluting stents were better than regular stents — they were actually worse.
Read More »NCHR Testimony on Low Nicotine Cigarette Claim
February 14, 2020. NCHR strongly opposes the approval of this modified risk application by the 22nd Century Group for their low-nicotine combusted filtered cigarette tobacco products. Evidence is lacking to support the claim that this product significantly reduces harm for smokers. At the same time, it is likely to entice people who have never smoked, especially adolescents, to start smoking.
Read More »FDA considers black box warning for all breast implants
WCPO Cincinnati, February 09, 2020. The FDA may finally require blackbox warnings for women considering breast implants, due to complications connected to implants after a mastectomy.
Read More »